| Is your age between 18 yrs and 70 yrs? |
|
|
|
| Are you female? |
|
|
|
| Do you have Locally Advanced Cervical Cancer? |
|
|
|
| Do you have any of these conditions: Do you have Locally Advanced Cervical Cancer?? |
|
|
|
| Is your age greater than or equal to 18 yrs? |
|
|
|
| Do you have any of these conditions: Do you have Locally Advanced Cervical Cancer?? |
|
|
|
| Is your age greater than or equal to 18 yrs? |
|
|
|
| Do you have any of these conditions: Do you have Locally Advanced Cervical Cancer?? |
|
|
|
| Stage IB1 and IIA cervical cancer with no regional lymph node metastases (N0) |
|
|
|
| Stage IVB cervical cancer with presence of distant metastases other than para-aortic lymph node metastases |
|
|
|
| Prior surgery for cervical cancer unless cone resection and paraaortic lymphadenectomy |
|
|
|
| Prior pelvic radiotherapy, other radiotherapy, chemotherapy or immunotherapy |
|
|
|
| Any malignancy other than the disease under study in the past 5 years excepting skin cancers such as BCC or SCC |
|
|
|
| Pregnant or lactating women, or intending to become pregnant during the study |
|
|
|
| For patient 70 years old with a G-8 score 14, unconfirmation of patient eligibility done by the onco-geriatrian at screening |
|
|
|
| History of clinically relevant cardiovascular disease, congestive heart failure (New York Heart Association [NYHA] Class II or greater), or a known left ventricular ejection fraction (LVEF) <50%, symptomatic coronary artery disease, poorly controlled cardiac arrhythmia, or myocardial infarction |
|
|
|
| Active inflammatory bowel disease, lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome |
|
|
|
| Serious infection requiring oral or IV antibiotics within 4 weeks prior to randomisation, including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia |
|
|
|
| Treatment with another investigational therapy within 30 days prior to initiation of the study drug |
|
|
|
| Major surgical procedure within 4 weeks prior to randomisation or anticipation of the need for a major surgical procedure during the study other than for diagnosis. The following are not considered a major surgical procedure and are therefore permitted |
|
|
|
| (i) placement of central venous access catheter(s) (e.g., port or similar) |
|
|
|
| (ii) surgical lymph node staging with no perioperative complications; (iii) |
|
|
|
| placement of ureteral catheters |
|
|
|
| \. History of severe allergic anaphylactic reactions to chimeric, human or |
|
|
|
| humanized antibodies, or fusion proteins |
|
|
|
| \. Known hypersensitivity to Chinese hamster ovary (CHO) cell products or |
|
|
|
| any component of the atezolizumab formulation |
|
|
|
| \. Any contraindication to the use of Cisplatin and/or carboplatin |
|
|
|
| \. History of autoimmune disease, including but not limited to myasthenia |
|
|
|
| gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus |
|
|
|
| rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis |
|
|
|
| associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjgren's |
|
|
|
| syndrome, Guillain-Barr syndrome, multiple sclerosis, meningoencephalitis, or |
|
|
|
| glomerulonephritis (see Appendix 6 for a more comprehensive list of autoimmune |
|
|
|
| diseases) with the following exceptions: patients with a history of |
|
|
|
| autoimmune-related hypothyroidism on a stable dose of thyroid replacement |
|
|
|
| hormone, patients with controlled Type 1 diabetes mellitus on a stable insulin |
|
|
|
| regimen, and patients with mild autoimmune skin disorders (such as eczema or |
|
|
|
| atopic dermatitis involving <10% of the skin) may be eligible for this study |
|
|
|
| \. History of idiopathic pulmonary fibrosis (IPF, including pneumonitis) |
|
|
|
| drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis |
|
|
|
| obliterans, cryptogenic organizing pneumonia), or active pneumonitis |
|
|
|
| \. Pre-existing hearing impairment |
|
|
|
| \. Peripheral neuropathy grade 2 |
|
|
|
| \. Positive test for human immunodeficiency virus (HIV) |
|
|
|
| \. Active hepatitis B (positive hepatitis B surface antigen [HBsAg] test at |
|
|
|
| screening) or hepatitis C (positive hepatitis C virus antibody [HCVAb] test at |
|
|
|
| screening). Note: Patients with past hepatitis B virus (HBV) infection or |
|
|
|
| resolved HBV infection (defined as having a negative HBsAg test and a positive |
|
|
|
| hepatitis B core antibody [HBcAb] test) are eligible |
|
|
|
| \. Known active tuberculosis |
|
|
|
| \. Receipt of a live, attenuated vaccine within 4 weeks prior to |
|
|
|
| randomisation or anticipation that such a live, attenuated vaccine will be |
|
|
|
| required during the study. Note: Patients must agree not to receive live |
|
|
|
| attenuated influenza vaccine (e.g., FluMist) within 28 days prior to |
|
|
|
| randomisation, during treatment or within 5 months following the last dose of |
|
|
|
| atezolizumab |
|
|
|
| \. Prior treatment with CD137 agonists, anti-PD-1, or anti-PD-L1 therapeutic |
|
|
|
| antibody or immune checkpoint targeting agents |
|
|
|